… Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with
celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non–small-…

… Our study indicated that adding celecoxib to palliative therapy prolongs the PFS of EGFR
wild-… Celecoxib combined with adjuvant therapy prolongs OS, and celecoxib plus neoadjuvant …

… Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to
standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 …

… A phase II trial combining celecoxib and preoperative … for suitable randomized, double-blind,
placebo-controlled trials, … of carboplatin and celecoxib, the authors found that celecoxib …

… ) study was a multicenter, randomized, phase II trial that … alone or docetaxel plus celecoxib
[400 mg twice per day orally] … 220]; or docetaxel alone or docetaxel plus trastuzumab for HER2…

… Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with
celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell …

… 2 of docetaxel and 4 mg of zoledronic acid [33]. However, a … In a phase III double blind
randomized clinical trial, the efficacy … celecoxib in combination with carboplatin and pemetrexed or …

… with one of three chemotherapy regimens: carboplatin (area … In our phase II randomized
study in 151 patients with locally … combination of methotrexate and celecoxib, we were unable …

… Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with
celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell …

… Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with
celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell …